Phosphorus-31 magnetic resonance spectroscopic study of skeletal muscle in hypertrophic cardiomyopathy

D. Duboc, P. Jehenson, J. F. Tamby, J. F. Payen, A. Syrota, F. Guerin

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

There have been several reports of electromyographic and histological changes of striated skeletal muscle, especially of the type I oxidative fibres, in hypertrophic cardiomyopathy. In order to determine whether these anomalies also cause metabolic changes, a P-31 magnetic resonance spectroscopic study was undertaken at rest and on exercise in 5 paucisymptomatic patients and 10 control subjects. The 5 patients had primary hypertrophic cardiomyopathy without alteration of systolic function or signs of congestive cardiac failure (Stages I or II). There were no clinical signs of myopathy. None of the patients were receiving betablocker therapy at the time of investigation. No significant difference was observed at rest. Intracellular acidosis was particularly pronounced in 2 of the 5 patients at the peak of exercise. In addition, the phosphocreatine recovery time (T 1/2 ) was longer in the patient group (3.4 ± 1.7 vs 1.6 ± 0.9 mn; p < 0.01) suggesting a mitochondrial metabolic oxidation abnormality. These results suggest that some patients with primary hypertrophic cardiomyopathy have abnormalities of mitochondrial oxidation in their striated skeletal muscle which can be demonstrated by P-31 magnetic resonance spectroscopy. This would suggest a global abnormality of striated muscle which, at a more advanced stage of the disease, could account for decreased effort tolerance in these patients.

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalArchives des Maladies du Coeur et des Vaisseaux
Volume84
Issue number2
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Phosphorus-31 magnetic resonance spectroscopic study of skeletal muscle in hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

Cite this